Cover Image
市場調查報告書

糖尿病的非胰島素療法:GLP-1受體激動劑、DPP4抑制劑、SGLT2抑制劑 (2016-2026年)

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

出版商 ROOTS ANALYSIS 商品編碼 367263
出版日期 內容資訊 英文 359 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病的非胰島素療法:GLP-1受體激動劑、DPP4抑制劑、SGLT2抑制劑 (2016-2026年) Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026
出版日期: 2016年08月11日 內容資訊: 英文 359 Pages
簡介

本報告提供糖尿病的非胰島素療法的市場調查,糖尿病的分類、診斷、治療概要,非胰島素治療藥種類與概要,主要的已通過核准藥、開發平台藥物概要,開發的過程、情形,劑型、收銀機麵條、價格,近幾年的聯盟,開發中止的候補分子,新的非胰島素療法的藥物類別、開發階段、各分子類型的分佈,主要產品的銷售額預測,KOL及出版物相關分析等彙整資料。

第1章 序章

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 糖尿病:簡介
    • 分類
    • 症狀
    • 診斷
    • 相關的健康上的風險、併發症
    • 治療方法
      • 胰島素療法
      • 非胰島素療法
        • AlphaGlucosidase抑制劑
        • Amylin受體激動劑
        • Biguanides
        • Dipeptidyl Peptidase4 (DPP4) 抑制劑
        • Glinides / Meglitinides
        • GLP-1類比 / GLP-1受體激動劑
        • 鈉/葡萄糖共同輸送體2 (SGLT2) 抑制劑
        • 磺醯尿素類劑
        • 胰島素增敏劑 (TZD)

第4章 市場概要

  • 本章概要
  • 非胰島素糖尿病治療藥:發展、演進的時間軸
  • GLP-1受體激動劑、DPP4抑制劑、SGLT2抑制劑:整體市場概要
  • GLP-1受體激動劑:目前市場環境
  • DPP4抑制劑:目前市場環境
  • SGLT2抑制劑:目前市場環境
    • 已通過核准藥
    • 開發平台藥物
    • 主要企業
    • 各治療類型分佈
    • 各投藥頻率分佈

第5章 GLP-1受體激動劑

  • 本章概要
  • Albiglutide (GSK)
  • Dulaglutide (Eli Lilly / 大日本住友製藥)
  • ITCA 650 (Intarcia Therapeutics / Servier)
  • Polyethylene Glycol Loxenatide / PEX 168 (Jiangsu Hansoh Pharmaceutical)
  • Semaglutide / NN9535 / NN9924 / OG217SC (Novo Nordisk/Emisphere)
  • Uni-E4 (Uni-Bio Science Group)
    • 產品概要
    • 開發情形、開發的過程
    • 主要的臨床實驗的結果等

第6章 DPP4抑制劑 / CD26抗原拮抗藥

  • 本章概要
  • Alogliptin (武田藥品工業 / Furiex Pharmaceuticals (現在Forest Laboratories))
  • Trelagliptin (武田藥品工業 / 3SBio)
  • Omarigliptin (Merck)
  • Evogliptin (Dong-A Pharmaceutical / Luye Pharma Group / Eurofarma / Geropharm / Alkem Labs)
  • Gosogliptin (SatRx / Pfizer)
  • Retagliptin (Jiangsu Hengrui Medicine)
    • 產品概要
    • 開發的過程
    • 劑型、收銀機麵條、價格
    • 銷售情況
    • 目前開發情形
    • 主要的臨床實驗的結果
    • 近幾年的聯盟等

第7章 SGLT2抑制劑

  • 本章概要
  • Canagliflozin (田邊三菱製藥 / Janssen / 第一三共)
  • Luseogliflozin (大正製藥 / 大正富山醫藥品 / Novartis)
  • Tofogliflozin (中外製藥 / Sanofi / 興和)
  • Empagliflozin (Boehringer Ingelheim / Eli Lilly)
  • Ipragliflozin (Astellas Pharma Inc. / 壽製藥 / MSD K.K.)
  • Bexagliflozin (Theracos)
  • Ertugliflozin (PF-04971729, MK-8835) (Pfizer /Merck)
  • Sotagliflozin (Lexicon/Sanofi)
    • 產品概要
    • 開發的過程
    • 劑型、服法、價格
    • 銷售情況
    • 目前開發情形
    • 主要的臨床實驗的結果
    • 近幾年的聯盟等

第8章 開發中止的分子、一般的副作用

  • 本章概要
  • DPP4抑制劑
    • 一般的副作用
    • 來自當局的警告
  • SGLT2抑制劑
    • 一般的副作用
    • 來自當局的警告
  • GLP-1受體激動劑
    • 一般的副作用
    • 來自當局的警告
  • 開發中止的分子
    • 各藥物類別、開發階段的分佈
    • 由於中止年的分佈

第9章 糖尿病的新非胰島素療法

  • 本章概要
  • 糖尿病的新的非胰島素療法
    • 各類藥物的分佈
    • 各開發階段的分佈
    • 各分子類型的分佈

第10章 市場預測

  • 本章概要
  • 預測手法
  • 糖尿病的非胰島素療法:整體市場
  • GLP-1受體激動劑的整體市場
    • liraglutide (1.2mg、1.8mg)
    • Exendin-4 / ITCA 650
    • Exenatide徐放製劑
    • Dulaglutide
    • Albiglutide
    • Lixisenatide
    • Semaglutide Subcutaneous
    • liraglutide / Insulin Degludec
    • Semaglutide Oral / OG217SC / NN9924
    • Exenatide
    • 其他
  • DPP4抑制劑的整體市場
    • Sitagliptin
    • Vildagliptin
    • Saxagliptin
    • Linagliptin
    • Alogliptin
    • Gosogliptin
    • 其他
  • SGLT2抑制劑的整體市場
    • Sotagliflozin
    • Empagliflozin
    • Canagliflozin
    • Dapagliflozin
    • Tofogliflozin
    • Ertugliflozin
    • Bexagliflozin
    • 其他

第11章 出版物分析

  • 本章概要
  • 調查範圍、調查手法
  • GLP-1受體激動劑:出版物清單
    • 各焦點藥物的分佈
    • 各主參數的分佈
  • DPP4抑制劑:出版物清單
    • 各焦點藥物的分佈
    • 各主參數的分佈
  • SGLT2抑制劑:出版物清單
    • 各焦點藥物的分佈
    • 各主參數的分佈

第12章 KOL分析

  • 本章概要
  • 調查範圍、調查手法
  • GLP-1受體激動劑
  • DPP4抑制劑
  • SGLT2抑制劑
    • 主要研究人員
    • 主要KOL

第13章 採訪

第14章 總論

第15章 附錄1:圖表

第16章 附錄2:企業清單

目錄
Product Code: RA10063

Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment options for diabetic patients worldwide. While insulin supplements and insulin based therapies represent a major portion of the anti-diabetic drugs market, non-insulin therapies are first line therapies designed especially for patients suffering from type II diabetes.

Sulfonylureas, biguanides, glinides, TZDs and alpha- glucosidase inhibitors were the first classes of non-insulin therapies to hit the market. Subsequently, incretin based therapies, such as GLP-1 agonists and DPP4 inhibitors, emerged as the standard of care for the treatment of type II diabetes. More recently, SGLT2 inhibitors have also been identified as an effective treatment solution for the same patient population. These three classes have captured a significant portion of the overall anti-diabetes market in a relatively short time span.

GLP-1 agonists and DPP4 inhibitors were introduced in the market over a decade ago while the first SGLT2 inhibitor was approved only in 2012. A number of drugs have emerged as blockbusters; examples include VICTOZA® (GLP-1 agonist), JANUVIA® / JANUMET® (DPP4 inhibitor) and INVOKANA® / INVOKAMET® (SGLT2 inhibitor).

Several companies, including both big pharmaceutical players and small to mid-sized companies, are active in this area. Companies engaged in developing anti-diabetic drug classes have actively entered into collaborations with other stakeholders to either acquire / develop / commercialize candidate therapies or for technology licensing. For instance, Tobira acquired the exclusive rights to develop and commercialize evogliptin from Dong-A ST in April 2016; Eli Lilly and Sumitomo Dainippon Pharma entered into a sales collaboration agreement for Trulicity® in July 2015; Novo Nordisk in-licensed Zosano's technology to develop a transdermal patch formulation of Novo's GLP-1 analogs, including semaglutide in February 2014; Takeda and Sanofi signed a co-promotion agreement for alogliptin in China in April 2013.

Recently issued FDA warnings specifically for DPP4 and SGLT2 inhibitors are likely to impact their adoption. However, new advances in drug development and the introduction of novel technologies are expected to help stakeholders operate within a proper framework and work towards eliminating the current gaps.

Synopsis

The "Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016-2026" report provides a comprehensive analysis of the current market landscape of these therapies and an informed opinion on how the market is likely to evolve over the next decade. The anti-diabetic drugs market broadly comprises of insulin and non-insulin therapies. Non-insulin therapies are further classified under various categories based on their respective mechanisms of action. Of the different types of non-insulin therapies, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors have been the most popular in the last few years. As mentioned earlier, these therapeutic classes have captured the attention of a number of pharmaceutical companies and drug developers worldwide. Several companies, including pharmaceutical giants, mid-sized players and start-ups, have come up with innovative technologies and novel formulations of these drug classes. Such advances have generated and sustained significant momentum in this segment of the industry. Specifically, GLP-1 agonists, which have been researched for several years, have a rich pipeline of clinical and preclinical molecules. DPP4 inhibitors currently have a relatively larger market share; however, they are now giving way to other relatively newer and emerging classes such as SGLT2 inhibitors.

During the course of our study, we identified over 80 molecules belonging to these three drugs classes. More than 70% of the candidates are currently under clinical / preclinical development; the efforts are actively being led by several companies. Focused primarily on these three classes of drugs, this report features:

  • An overview of the market landscape highlighting important details on each molecule such as key players, current phase of product development, route of administration and dosage regime.
  • Detailed profiles of drugs that have been recently approved / marketed or are in the late stages of development.
  • A list of key opinion leaders (KOLs) who were involved in the discovery and development of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors.
  • An analysis of recently published clinical trial data depicting the prevalent trends and technical developments that have taken place in the industry.
  • A discussion on the potential side effects and warnings issued by regulatory authorities suggesting areas of improvement / guidance for future drug development.
  • A list of upcoming non-insulin novel therapies that are currently in early stages of development and likely to become a part of the anti-diabetic drugs market in the near future.

The report also provides an estimate of the likely future size of the non-insulin therapies for diabetes. Our forecast model was built based on an understanding of the existing market trends and likely future opportunities for GLP-1 agonists, DPP4 inhibitors, SGLT2 inhibitors and other non-insulin anti-diabetic drug classes. We have provided informed estimates of the expected future sales of marketed and late stage product candidates under each category, highlighting their share in the overall market over the next ten years.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzedfrom publicly available data. Unless otherwise specified, all financial figures are presented in USD.

Example Highlights

  • 1. With a current total / combined share of more than 70% in the overall non-insulin market, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors represent the three most prominent anti-diabetic drug classes. In terms of size, currently, the market of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors is worth over USD 4 billion, USD 10 billion and USD 2 billion respectively. Overall, the market is highly fragmented and well distributed across different regions.
  • 2. Combined, the three drug classes have over 20 approved drugs (accounting around 40 different formulations / fixed-dose combinations) for the treatment of type II diabetes. In addition, the clinical / preclinical pipeline is rich and has over 70 molecules in different stages of development. Of the three classes, DPP4 inhibitors currently has the maximum number of marketed drugs (over 10, excluding fixed-dose combinations). On the other hand, GLP-1 agonists represent the most active class of drugs with over 40 molecules under development. SGLT2 inhibitors are also emerging at a rapid pace and already have six marketed drugs across different regions. Semaglutide (Novo Nordisk), ITCA 650 (Intarcia Therapeutics), sotagliflozin (Sanofi / Lexicon Pharmaceuticals), ertugliflozin (Merck / Pfizer), retagliptin (Jiangsu Hengrui Medicine) and gosogliptin (SatRx / Pfizer) are examples of late stage drugs that are likely to receive approval in the near future.
  • 3. Overall we came across over 80 pharmaceutical companies actively engaged in the discovery, development and commercialization of non-insulin therapies. Established pharmaceutical players have captured a major share of the non-insulin anti-diabetic drugs market. In fact, AstraZeneca, BMS, Eli Lilly and Sanofi are developing non-insulin therapies across all the three drug classes. Several other companies such as Daiichi Sankyo, Janssen, Merck, Mitsubishi Tanabe Pharma, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda and Zealand Pharma have invested heavily in the development of multiple molecules belonging to these drug classes. A number of start-ups / small companies such as (in alphabetical order) Alteogen, Amunix, ArisGen, C4XD, Diartis Pharmaceuticals, Oramed Pharmaceutical, PegBio, Poxel, Rani Therapeutics, Receptos, SatRx, Sirona Biochem and Spitfire Pharma have entered this space and are also competing to gain a significant share in the overall non-insulin therapies market.
  • 4. In addition to increased competition of such therapies in the major geographies such as the US and EU, some stakeholders have focused on tapping a localized opportunity. Drugs such as teneligliptin (Mitsubishi Tanabe Pharma), trelagliptin (Takeda), ipragliflozin (Astellas Pharma/ Kotobuki Pharmaceutical) and luseogliflozin (Taisho Pharmaceutical) have been approved only in Japan. Similarly, retagliptin (Jiangsu Hengrui Medicine) and Uni-E4 (Uni-Bio Science Group) are in Phase III clinical development in China only.
  • 5. With a vision to increase patient compliance, several pharmaceutical companies have introduced fixed-dose formulations of different drugs. Prominent examples include Eucreas® / Galvumet® / Galvus Met® / Icandra® / Zomarist® (vildagliptin + metformin) (Novartis), INVOKAMET® / VOKANAMET® (canagliflozin + metformin) (Janssen Pharmaceutical Companies / Mitsubishi Tanabe Pharma / Daiichi Sankyo), JANUMET® / Velmetia® (sitagliptin + metformin) (Merck), Xigdua® (dapagliflozin + metformin) (Astra Zeneca / BMS) and Xultophy® / IDegLira (liraglutide + insulin degludec) (Novo Nordisk).
  • 6. Technological advancements are amongst the key future growth drivers. Drug developers are investigating new routes of administration using several innovative technology platforms, such as Axcess™ (Diabetology), Eligen® (Emisphere Technologies), PharmFilm® Technology (MonoSol Rx) and the Protein Oral Delivery (POD™) technology (Oramed Pharmaceuticals), to facilitate the oral administration of GLP-1 agonists. Other innovative technologies such as the Intravail® drug delivery platform are attempting to facilitate nasal administration.Companies such as ScinoPharm and Panacea Biotech are developing oral capsule formulations of DPP4 inhibitors. Their molecules, DBPR108 and PBL 1427, respectively, are still in the early stages of clinical development.SGLT2 inhibitors, primarily used to treat type II diabetes, are also being developed for the treatment of type I diabetes. Examples include sotagliflozin (Theracos) and remogliflozin (BHV Pharma).
  • 7. Dual agonist drugs are also being developed to provide more effective treatment options. Examples of molecules that target both the GLP-1 receptor and glucagon receptor include MK-8521 (Merck), TTP401 / LY2944876 (Transition Therapeutics / Eli Lilly), MEDI0382 (AstraZeneca), SAR425899 (Sanofi) and MOD-6030 / MOD-6031 (OPKO Biologics). On the other hand, NN9709 (Novo Nordisk) and SAR438335 (Sanofi) are being developed to act on both GLP-1 and GIP receptors.
  • 8. Several research institutes, companies and organization have made significant contribution to the discovery and overall development of these therapies. During the study, we identified over 400 key opinion leaders who have played critical role in the development of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. In addition, we identified over 50 articles, published during the 12 months beginning January 2015, which focused on these three drug classes. The design of these studies primarily focussed on evaluating the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of the drugs.
  • 9. Extensive efforts are being made by pharmaceutical companies to explore new and innovative therapeutic strategies and agents that are safer and more effective than the already available options. Many novel non-insulin therapies are under clinical development. Examples of these new anti-diabetic drug classes include glucokinase activators, GPR119 agonists, GCGR antagonists, 11-beta hydroxysteroid dehydrogenase type 1 inhibitors, glycogen phosphorylase inhibitors and PTP-1B antagonists.
  • 10. It is important to highlight that nearing patent expiries of currently available drugs and the potential health hazards associated with the use of some of these inhibitors are going to negatively impact the market growth. However, our overall outlook is highly promising. We believe that SGLT2 inhibitors are likely to grow at an annualized growth rate of ~17%, followed by GLP-1 agonists (expected growth rate of ~13.4%).

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors during the coming decade.

Chapter 3 provides a general introduction to diabetes and discusses associated symptoms, available diagnostic methods and tests, and other complications associated with the condition. It also includes a detailed classification of the various therapeutic interventions available for the treatment of diabetes. These include both insulin based and non-insulin therapies. The chapter also provides brief descriptions of their respective mechanisms of action.

Chapter 4 provides a comprehensive overview of the market landscape of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. It includes information on over 100 different molecules that fall under these classes of drugs. Some of these are already approved and are available in different regions across the globe. The rest are currently in various stages of preclinical / clinical development. The chapter presents analysis of the molecules based on their current phase of development, the various routes of administration being considered for their systemic delivery, dosage frequency, type of molecule and key players involved in developing these molecules.

Chapter 5 contains detailed profiles of recently approved and late stage GLP-1 agonists. Each profile covers information on several aspects of these drugs such as their history of development, clinical trial results, dosage form and regime, recent sales of the product (for marketed drugs), the current status of development, and the collaborations and partnerships that have been inked related to that particular drug / drug candidate.

Chapter 6 contains detailed profiles of recently approved and late stage DPP4 inhibitors. Each profile covers information on several aspects of these drugs such as their history of development, clinical trial results, dosage form and regime, recent sales of the product (for marketed drugs), the current status of development, and the collaborations and partnerships that have been inked related to that particular drug / drug candidate.

Chapter 7 contains detailed profiles of recently approved and late stage SGLT2 inhibitors. Each profile covers information on several aspects of these drugs such as their history of development, clinical trial results, dosage form and regime, recent sales of the product (for marketed drugs), the current status of development, and the collaborations and partnerships that have been inked related to that particular drug / drug candidate.

Chapter 8 focusses on the various side effects reported by patients treated using these drugs. It includes detailed discussions on the potential complications that may arise upon using these drugs, and the warnings issued by the FDA and other regulatory bodies regarding the associated risks. In addition, the chapter lists the various GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors that have been terminated during development due to various reasons.

Chapter 9 provides a brief introduction to other novel interventions that are currently being investigated as potential treatment options for diabetes. The chapter also includes an analysis of these novel therapeutic options based on the type of molecule being investigated and phase of development.

Chapter 10 provides a detailed analysis on the likely future size of the non-insulin therapies market over the next decade. It presents comprehensive forecast scenarios for each individual drug class mentioned in the report, namely GLP-1 agonists, DPP4 inhibitors, SGLT2 inhibitors and other non-insulin anti-diabetic drugs.

Chapter 11 presents an analysis of the Key Opinion Leaders (KOLs) in this domain. It contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers. The chapter presents a detailed 2X2 analysis to assess the relative experience of certain KOLs based on the number of clinical studies they participated in and the highest phase of development they investigated.

Chapter 12 provides a detailed analysis of recently published clinical data on GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. It identifies various aspects of the ongoing research and presents analysis highlighting the active drugs, study focus areas and clinical endpoints (safety / efficacy / tolerability / pharmacodynamics / pharmacokinetics) across the published data.

Chapter 13 is a collection of interview transcripts of the discussions we held with key stakeholders in the industry.

Chapter 14 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix,which contains the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Introduction

  • 3.1. Chapter Overview
  • 3.2. Diabetes: Introduction
    • 3.2.1. Diabetes: Classification
    • 3.2.2. Diabetes: Symptoms
    • 3.2.3. Diabetes: Diagnosis
    • 3.2.4. Diabetes: Associated Health Risks / Complications
    • 3.2.5. Diabetes: Therapies
      • 3.2.5.1. Insulin Therapies
      • 3.2.5.2. Non-Insulin Therapies
        • 3.2.5.2.1. Alpha-glucosidase Inhibitors
        • 3.2.5.2.2. Amylin Agonists
        • 3.2.5.2.3. Biguanides
        • 3.2.5.2.4. Dipeptidyl peptidase-4 (DPP4) inhibitors
        • 3.2.5.2.5. Glinides / Meglitinides
        • 3.2.5.2.6. GLP-1 Analogs / GLP-1 Agonists
        • 3.2.5.2.7. Sodium-glucose cotransporter 2 (SGLT2) Inhibitors
        • 3.2.5.2.8. Sulfonylureas
        • 3.2.5.2.9. Thiazolidinediones (or 'glitazones'or TZDs)

4. Market Overview

  • 4.1. Chapter Overview
  • 4.2. Non-Insulin Anti-Diabetic Therapies: History of Development / Evolution Timeline
  • 4.3. GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Overall Market Overview
  • 4.4. GLP-1 Agonists: Current Market Landscape
    • 4.4.1. GLP-1 Agonists: Approved Drugs
    • 4.4.2. GLP-1 Agonists: Pipeline Drugs
    • 4.4.3. GLP-1 Agonists: Key Players
    • 4.4.4. GLP-1 Agonists: Distribution by Route of Administration
    • 4.4.5. GLP-1 Agonists: Distribution by Dosage Frequency
    • 4.4.6. GLP-1 Agonists: Distribution by Type of Molecule
  • 4.5. DPP4 Inhibitors: Current Market Landscape
    • 4.5.1. DPP4 Inhibitors: Approved Drugs
    • 4.5.2. DPP4 Inhibitors: Pipeline Drugs
    • 4.5.3. DPP4 Inhibitors: Key Players
    • 4.5.4. DPP4 Inhibitors: Distribution by Type of Therapy
    • 4.5.5. DPP4 Inhibitors: Distribution by Dosage Frequency
  • 4.6. SGLT2 Inhibitors: Current Market Landscape
    • 4.6.1. SGLT2 Inhibitors: Approved Drugs
    • 4.6.2. SGLT2 Inhibitors: Pipeline Drugs
    • 4.6.3. SGLT2 Inhibitors: Key Players
    • 4.6.4. SGLT2 Inhibitors: Distribution by Type of Therapy
    • 4.6.5. SGLT2 Inhibitors: Distribution by Dosage Frequency
  • 4.7. GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Key Players

5. GLP-1 Agonists

  • 5.1. Chapter Overview
  • 5.2. Albiglutide (GSK)
    • 5.2.1. Product Overview
    • 5.2.2. History of Development
    • 5.2.3. Dosage Form, Regimen and Price
    • 5.2.4. Historical Sales
    • 5.2.5. Current Status of Development
    • 5.2.6. Key Clinical Trial Results
      • 5.2.6.1. Harmony 1 Study (Abstract Number: 2013-LB-5644)
      • 5.2.6.2. Harmony 2 Study (Abstract Number: 2013-LB-5749)
      • 5.2.6.3. Harmony 3 Study (Abstract Number: 2013-LB-5750)
      • 5.2.6.4. Harmony 4 Study (Abstract number: 2013-LB-5751)
      • 5.2.6.5. Harmony 5 Study (Abstract Number: 2013-LB-5752)
      • 5.2.6.6. Harmony 6 Study
      • 5.2.6.7. Harmony 7 Study
      • 5.2.6.8. Harmony 8 Study
    • 5.2.7. Recent Collaborations
  • 5.3. Dulaglutide (Eli Lilly / Sumitomo Dainippon Pharma)
    • 5.3.1. Product Overview
    • 5.3.2. History of Development
    • 5.3.3. Dosage Form, Regimen and Price
    • 5.3.4. Historical Sales
    • 5.3.5. Current Status of Development
    • 5.3.6. Key Clinical Trial Results
      • 5.3.6.1. AWARD-1
      • 5.3.6.2. AWARD-2
      • 5.3.6.3. AWARD-3
      • 5.3.6.4. AWARD-4
      • 5.3.6.5. AWARD-5
      • 5.3.6.6. AWARD-6
      • 5.3.6.7. AWARD-8
      • 5.3.6.8. AWARD-9
      • 5.3.6.9. Trulicity® versus Lantus®
      • 5.3.6.10. Trulicity® versus Victoza®
    • 5.3.7. Recent Collaborations
  • 5.4. ITCA 650 (Intarcia Therapeutics / Servier)
    • 5.4.1. Product Overview
    • 5.4.2. History of Development
    • 5.4.3. Intarcia's Technology Platform
    • 5.4.4. Current Status of Development
    • 5.4.5. Key Clinical Trial Results
      • 5.4.5.1. FREEDOM 1 HBL: Interim Results
      • 5.4.5.2. FREEDOM-1 and FREEDOM-1 HBL: Top-Line Results
      • 5.4.5.3. FREEDOM-2 Comparative Trial: Top-Line Results
      • 5.4.5.4. FREEDOM-CVO: Top-Line Results
    • 5.4.6. Funding
    • 5.4.7. Recent Collaborations
  • 5.5. Polyethylene Glycol Loxenatide / PEX 168 (Jiangsu Hansoh Pharmaceutical)
    • 5.5.1. Product Overview
    • 5.5.2. Current Status of Development
    • 5.5.3. Key Clinical Trial Results
  • 5.6. Semaglutide / NN9535 / NN9924 / OG217SC (Novo Nordisk/Emisphere)
    • 5.6.1. Product Overview
    • 5.6.2. History of Development
    • 5.6.3. NN9924 and the Eligen® Technology
    • 5.6.4. Manufacturing
    • 5.6.5. Dosage Form and Regimen
    • 5.6.6. Current Status of Development
      • 5.6.6.1. PIONEER Clinical Program
      • 5.6.6.2. SUSTAIN Clinical Program
    • 5.6.7. Key Clinical Trial Results
      • 5.6.7.1. NN9535: Phase III Results
      • 5.6.7.2. NN9924/OG217SC: Phase II Results
    • 5.6.8. Recent Collaborations
  • 5.7. Uni-E4 (Uni-Bio Science Group)
    • 5.7.1. Product Overview
    • 5.7.2. Key Clinical Trial Results

6. DPP4 Inhibitors / CD26 Antigen Antagonists

  • 6.1. Chapter Overview
  • 6.2. Alogliptin (Takeda / Furiex Pharmaceuticals (Acquired by Forest Laboratories))
    • 6.2.1. Product Overview
    • 6.2.2. History of Development
    • 6.2.3. Dosage Form, Regimen and Price
    • 6.2.4. Historical Sales
    • 6.2.5. Current Status of Development
    • 6.2.6. Key Clinical Trial Results
      • 6.2.6.1. EXAMINE Program
      • 6.2.6.2. ENDURE Trial
    • 6.2.7. Recent Collaborations
  • 6.3. Trelagliptin (Takeda / 3SBio)
    • 6.3.1. Product Overview
    • 6.3.2. History of Development
    • 6.3.3. Dosage Form, Regimen and Price
    • 6.3.4. Current Status of Development
    • 6.3.5. Key Clinical Trial Results
    • 6.3.6. Recent Collaborations
  • 6.4. Omarigliptin (Merck)
    • 6.4.1. Product Overview
    • 6.4.2. History of Development
    • 6.4.3. Current Status of Development
    • 6.4.4. Key Clinical Trial Results
  • 6.5. Evogliptin (Dong-A Pharmaceutical / Luye Pharma Group / Eurofarma / Geropharm / Alkem Labs)
    • 6.5.1. Product Overview
    • 6.5.2. Dosage Forms, Regimen and Price
    • 6.5.3. Current Status of Development
    • 6.5.4. Key Clinical Trial Results
    • 6.5.5. Recent Collaborations
  • 6.6. Gosogliptin (SatRx / Pfizer)
    • 6.6.1. Product Overview
    • 6.6.2. Current Status of Development
    • 6.6.3. Recent Collaborations
  • 6.7. Retagliptin (Jiangsu Hengrui Medicine)
    • 6.7.1. Product Overview
    • 6.7.2. Current Status of Development

7. SGLT2 Inhibitors

  • 7.1. Chapter Overview
  • 7.2. Canagliflozin (Mitsubishi Tanabe Pharma / Janssen / Daiichi Sankyo)
    • 7.2.1. Product Overview
    • 7.2.2. History of Development
    • 7.2.3. Dosage Form, Regimen and Price
    • 7.2.4. Historical Sales
    • 7.2.5. Current Status of Development
    • 7.2.6. Key Clinical Trial Results
      • 7.2.6.1. Long Term Effects in Older Type II Diabetic Patients
      • 7.2.6.2. Real-World Analysis
      • 7.2.6.3. Comparison between INVOKANA® and Other DPP4 Inhibitors
    • 7.2.7. Recent Collaborations
  • 7.3. Luseogliflozin (Taisho Pharmaceutical / Taisho Toyama Pharmaceutical / Novartis)
    • 7.3.1. Product Overview
    • 7.3.2. History of Development
    • 7.3.3. Dosage Form, Regimen and Price
    • 7.3.4. Current Status of Development
    • 7.3.5. Key Clinical Trial Results
      • 7.3.5.1. As a Monotherapy
        • 7.3.5.1.1. Study 1: Placebo Controlled (24 weeks)
        • 7.3.5.1.2. Study 2: Long-Term Treatment (52 weeks)
      • 7.3.5.2. As Combination Therapy
        • 7.3.5.2.1. Study 1: Combination with Glimepiride
        • 7.3.5.2.2. Study 2: Combination with Metformin, DPP4 inhibitor, Pioglitazone, Glinides or alpha-glucosidase inhibitor
    • 7.3.6. Historical Sales
    • 7.3.7. Recent Collaborations
  • 7.4. Tofogliflozin (Chugai Pharmaceutical / Sanofi / Kowa)
    • 7.4.1. Product Overview
    • 7.4.2. History of Development
    • 7.4.3. Current Status of Development
    • 7.4.4. Key Clinical Trial Results
    • 7.4.4.1. As a Monotherapy
    • 7.4.5. Recent Collaborations
  • 7.5. Empagliflozin (Boehringer Ingelheim / Eli Lilly)
    • 7.5.1. Product Overview
    • 7.5.2. History of Development
    • 7.5.3. Dosage Form, Regimen and Price
    • 7.5.4. Manufacturing
    • 7.5.5. Current Status of Development
    • 7.5.6. Key Clinical Trial Results
      • 7.5.6.1. As a Monotherapy: Retrospective Data
      • 7.5.6.2. As a Fixed-Dose Combination Therapy
        • 7.5.6.2.1. Combination with Metformin
        • 7.5.6.2.2. Combination with Linagliptin
      • 7.5.6.3. CV Outcome Results (EMPA-REG OUTCOME®)
    • 7.5.7. Recent Collaborations
  • 7.6. Ipragliflozin (Astellas Pharma / Kotobuki Pharmaceutical / MSD K.K.)
    • 7.6.1. Product Overview
    • 7.6.2. History of Development
    • 7.6.3. Dosage Form, Regimen and Price
    • 7.6.4. Current Status of Development
    • 7.6.5. Key Clinical Trial Results
      • 7.6.5.1. As a Monotherapy
      • 7.6.5.2. As a Combination Therapy
    • 7.6.6. Recent Collaborations
  • 7.7. Bexagliflozin (Theracos)
    • 7.7.1. Product Overview
    • 7.7.2. Current Status of Development
    • 7.7.3. Key Clinical Trial Results
  • 7.8. Ertugliflozin (PF-04971729, MK-8835) (Pfizer /Merck)
    • 7.8.1. Product Overview
    • 7.8.2. Current Status of Development
    • 7.8.3. Key Clinical Trial Results
      • 7.8.3.1. As a Monotherapy: VERTIS Mono
      • 7.8.3.2. As a Combination Therapy with JANUVIA®: VERTIS Factorial
    • 7.8.4. Recent Collaborations
  • 7.9. Sotagliflozin (Lexicon/Sanofi)
    • 7.9.1. Product Overview
    • 7.9.2. History of Development
    • 7.9.3. Current Status of Development
    • 7.9.4. Key Clinical Trial Results
      • 7.9.4.1. Type I Diabetes: Phase II Results
      • 7.9.4.2. Type II Diabetes: Phase IIb Results
      • 7.9.4.3. Type II Diabetes: Phase IIa Results
      • 7.9.4.4. Type I Diabetes / Type II Diabetes with Renal Impairment
      • 7.9.4.5. As a Combination Therapy
    • 7.9.5. Recent Collaborations

8. Discontinued Molecules and Common Side Effects

  • 8.1. Chapter Overview
  • 8.2. DPP4 Inhibitors
    • 8.2.1. Common Side Effects
    • 8.2.2. Warnings Issued by Regulatory Agencies
  • 8.3. SGLT2 Inhibitors
    • 8.3.1. Common Side Effects
    • 8.3.2. Warnings issued by Regulatory Agencies
  • 8.4. GLP-1 Agonists
    • 8.4.1. Common Side Effects
    • 8.4.2. Warnings Issued by Regulatory Agencies
  • 8.5. DPP4 Inhibitors, GLP-1 Agonists, SGLT2 Inhibitors: Terminated Molecules
    • 8.5.1. Distribution by Type of Drug Class and Phase of Development
    • 8.5.2. Distribution by Year of Termination

9. Novel Non-Insulin Therapies for Diabetes

  • 9.1. Chapter Overview
  • 9.2. Novel Non-Insulin Therapies for Diabetes
    • 9.2.1. Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Drug Class
    • 9.2.2. Novel Non-Insulin Therapies for Diabetes: Distribution by Phase of Development
    • 9.2.3. Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Molecule

10. Market Forecast

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology
  • 10.3. Overall Non-Insulin Therapies for Diabetes Market
  • 10.4. Overall GLP-1 Agonists Market
    • 10.4.1. Liraglutide (1.2mg and 1.8mg)
    • 10.4.2. Exendin-4 / ITCA 650
    • 10.4.3. Exenatide Extended Release
    • 10.4.4. Dulaglutide
    • 10.4.5. Albiglutide
    • 10.4.6. Lixisenatide
    • 10.4.7. Semaglutide Subcutaneous
    • 10.4.8. Liraglutide / Insulin Degludec
    • 10.4.9. Semaglutide Oral / OG217SC / NN9924
    • 10.4.10. Exenatide
    • 10.4.11. Other GLP-1 Agonists
  • 10.5. Overall DPP4 Inhibitors Market
    • 10.5.1. Sitagliptin
    • 10.5.2. Vildagliptin
    • 10.5.3. Saxagliptin
    • 10.5.4. Linagliptin
    • 10.5.5. Alogliptin
    • 10.5.6. Gosogliptin
    • 10.5.7. Other DPP4 Inhibitors
  • 10.6. Overall SGLT2 Inhibitors Market
    • 10.6.1. Sotagliflozin
    • 10.6.2. Empagliflozin
    • 10.6.3. Canagliflozin
    • 10.6.4. Dapagliflozin
    • 10.6.5. Tofogliflozin
    • 10.6.6. Ertugliflozin
    • 10.6.7. Bexagliflozin
    • 10.6.8. Other SGLT2 Inhibitors

11. Publication Analysis

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. GLP-1 Agonists: List of Publications
    • 11.3.1. Publications on GLP-1 Agonists: Distribution by Focus Drug
    • 11.3.2. Publications on GLP-1 Agonists: Distribution by Key Parameters
  • 11.4. DPP4 Inhibitors: List of Publications
    • 11.4.1. Publications on DPP4 Inhibitors: Distribution by Focus Drug
    • 11.4.2. Publications on DPP4 Inhibitors: Distribution by Key Parameters
  • 11.5. SGLT2 Inhibitors: List of Publications
    • 11.5.1. Publications on SGLT2 Inhibitors: Distribution by Focus Drug
    • 11.5.2. Publications on SGLT2 Inhibitors: Distribution by Key Parameters

12. KOL Analysis

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. GLP-1 Agonists: Key Opinion Leaders
    • 12.3.1. GLP-1 Agonists: Prominent Researchers
    • 12.3.2. GLP-1 Agonists: Leading Key Opinion Leaders
  • 12.4. DPP4 Inhibitors: Key Opinion Leaders
    • 12.4.1. DPP4 Inhibitors: Prominent Researchers
    • 12.4.2. DPP4 Inhibitors: Leading Key Opinion Leaders
  • 12.5. SGLT2 Inhibitors: Key Opinion Leaders
    • 12.5.1. SGLT2 Inhibitors: Prominent Researchers
    • 12.5.2. SGLT2 Inhibitors: Leading Key Opinion Leaders

13. Interview Transcripts

14. Conclusion

  • 14.1. The Lucrative Anti-Diabetic Drugs Market Presents Immense Opportunity to Novel Non-Insulin Therapies
  • 14.2. GLP-1 Inhibitors and DPP4 Inhibitors Currently Dominate; SGLT2 Inhibitors Have Shown Significant Promise
  • 14.3. Companies Targeting Certain Regional Markets are Amongst the Primary Drivers
  • 14.4. Technological Advances and Innovative Drug Development Approaches are Key to Future Success
  • 14.5. Development of Combination Therapies and Several Novel Drug Classes Are Expected to Promote Future Growth
  • 14.6. Multiple Side Effects Associated with the Use of Certain Drug Classes Remain a Concern
  • 14.7. While the Respective Shares of GLP-1 Agonists and SGLT2 Inhibitors are Projected to Increase, Sales of DPP4 Inhibitors Are Likely to Dip

15. Appendix 1: Tabulated Data

16. Appendix 2: List of Companies and Organizations

List of Figures

  • Figure 3.1 Diabetes: Diagnostic Limits
  • Figure 3.2 Non-Insulin Therapies for Diabetes
  • Figure 4.1 Non-Insulin Therapies: Distribution by Drug Class
  • Figure 4.2 GLP-1 Agonists: Distribution by Phase of Development
  • Figure 4.3 GLP-1 Agonists: Key Players
  • Figure 4.4 GLP-1 Agonists: Distribution by Route of Administration
  • Figure 4.5 GLP-1 Agonists: Distribution by Dosage Frequency
  • Figure 4.6 GLP-1 Agonists: Distribution by Type of Molecule
  • Figure 4.7 DPP4 Inhibitors: Distribution by Phase of Development
  • Figure 4.8 DPP4 Inhibitors: Key Players
  • Figure 4.9 DPP4 Inhibitors: Distribution by Type of Therapy
  • Figure 4.10 DPP4 Inhibitors: Distribution by Dosage Frequency
  • Figure 4.11 SGLT2 Inhibitors: Distribution by Phase of Development
  • Figure 4.12 SGLT2 Inhibitors: Key Players
  • Figure 4.13 SGLT2 Inhibitors: Distribution by Type of Therapy
  • Figure 4.14 SGLT2 Inhibitors: Distribution by Dosage Frequency
  • Figure 4.15 GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Key Players
  • Figure 5.1 Tanzeum® / Eperzan®: Historical Sales, 2014-Q12016 (GBP Million)
  • Figure 5.2 Trulicity®: Historical Sales, 2014-2015 (USD Million)
  • Figure 5.3 Trulicity® Historical Sales: Distribution by Region, 2015 (USD Million)
  • Figure 5.4 ITCA 650: FREEDOM-1 and FREDDOM-1 HBL Clinical Trials
  • Figure 6.1 Alogliptin: History of Development
  • Figure 6.2 Alogliptin: Historical Sales, FY2011-Q1 FY2016 (JPY Billion)
  • Figure 6.3 Alogliptin Historical Sales: Distribution by Region, FY2015 (JPY Billion)
  • Figure 7.1 Canagliflozin: History of Development
  • Figure 7.2 INVOKANA® / INVOKAMET®: Historical Sales, 2013-Q1 2016 (USD Million)
  • Figure 7.3 INVOKANA® / INVOKAMET® Historical Sales: Distribution by Region, 2015-Q1 2016 (USD Million)
  • Figure 7.4 Empagliflozin: History of Development
  • Figure 7.5 Ipragliflozin: History of Development
  • Figure 8.1 Terminated Molecules: Distribution by Type of Drug Class
  • Figure 8.2 Terminated Molecules: Distribution by Type of Drug Class and Phase of Development
  • Figure 8.3 Terminated Molecules: Distribution by Type of Drug Class and Year of Termination
  • Figure 9.1 Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Drug Class
  • Figure 9.2 Novel Non-Insulin Therapies for Diabetes: Distribution by Phase of Development
  • Figure 9.3 Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Molecule
  • Figure 10.1 Non-Insulin Therapies for Diabetes Market, 2016-2026 (USD Billion)
  • Figure 10.2 Non-Insulin Therapies for Diabetes Market, 2016-2026: Future Trends and Details
  • Figure 10.3 Non-Insulin Therapies for Diabetes Market, 2016, 2021 and 2026: Distribution by Type of Drug Class
  • Figure 10.4 GLP-1 Agonists Market, 2016-2026 (USD Billion)
  • Figure 10.5 Liraglutide (1.2mg and 1.8mg) Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.6 Exendin-4 / ITCA 650 Sales Forecast, 2017-2026 (USD Million)
  • Figure 10.7 Exenatide Extended Release Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.8 Dulaglutide Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.9 Albiglutide Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.10 Lixisenatide Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.11 Semaglutide/NN9535 Sales Forecast, 2018-2026 (USD Million)
  • Figure 10.12 Liraglutide / Insulin Degludec Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.13 Semaglutide Oral / OGC217SC / NN9924 Sales Forecast, 2020-2026 (USD Million)
  • Figure 10.14 Exenatide Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.15 DPP4 Inhibitors Market, 2016-2026 (USD Billion)
  • Figure 10.16 Sitagliptin Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.17 Vildagliptin Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.18 Saxagliptin Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.19 Linagliptin Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.20 Alogliptin Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.21 Gosogliptin Sales Forecast, 2017-2026 (USD Million)
  • Figure 10.22 SGLT2 Inhibitors Market, 2016-2026 (USD Billion)
  • Figure 10.23 Sotagliflozin Sales Forecast, 2018-2026 (USD Million)
  • Figure 10.24 Empagliflozin Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.25 Canagliflozin Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.26 Dapagliflozin Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.27 Tofogliflozin Sales Forecast, 2016-2026 (USD Million)
  • Figure 10.28 Ertugliflozin Sales Forecast, 2018-2026 (USD Million)
  • Figure 10.29 Bexagliflozin Sales Forecast, 2018-2026 (USD Million)
  • Figure 11.1 Publications on GLP-1 Agonists: Distribution by Focus Drug
  • Figure 11.2 Publications on GLP-1 Agonists: Distribution by Study Focus, Publication Month and other Parameters
  • Figure 11.3 Publications on DPP4 Inhibitors: Distribution by Focus Drug
  • Figure 11.4 Publications on DPP4 Inhibitors: Distribution by Study Focus, Publication Month and other Parameters
  • Figure 11.5 Publications on SGLT2 Inhibitors: Distribution by Focus Drug
  • Figure 11.6 Publications on SGLT2 Inhibitors: Distribution by Study Focus, Publication Month and other Parameters
  • Figure 12.1 GLP-1 Agonists: Mapping Prominent Researchers
  • Figure 12.2 GLP-1 Agonists: Leading Key Opinion Leaders
  • Figure 12.3 DPP4 Inhibitors: Mapping Prominent Researchers
  • Figure 12.4 DPP4 inhibitors: Leading Key Opinion Leaders
  • Figure 12.5 SGLT2 Inhibitors: Mapping Prominent Researchers
  • Figure 12.6 SGLT2 Inhibitors: Leading Key Opinion Leaders
  • Figure 14.1 Overall Non-Insulin Therapies Market Forecast: Distribution by Drug Class, 2016-2026 (USD Billion)

List of Tables

  • Table 4.1 Anti-Diabetic Drug Classes: History of Development
  • Table 4.2 GLP-1 Agonists: Approved Drugs
  • Table 4.3 GLP-1 Agonists: Pipeline Drugs
  • Table 4.4 DPP4 Inhibitors: Approved Drugs
  • Table 4.5 DPP4 Inhibitors: Pipeline Drugs
  • Table 4.6 SGLT2 Inhibitors: Approved Drugs
  • Table 4.7 SGLT2 Inhibitors: Pipeline Drugs
  • Table 5.1 Albiglutide: Product Overview
  • Table 5.2 Albiglutide: Active / Planned Clinical Trials
  • Table 5.3 Albiglutide Harmony 2 Clinical Trial: Adverse Events
  • Table 5.4 Albiglutide Harmony 3 Clinical Trial: Adverse Events
  • Table 5.5 Albiglutide Harmony 4 Clinical Trial: Adverse Events
  • Table 5.6 Albiglutide Harmony 5 Clinical Trial: Adverse Events
  • Table 5.7 Albiglutide Harmony 6 Clinical Trial: Results
  • Table 5.8 Albiglutide Harmony 6 Clinical Trial: Adverse Events
  • Table 5.9 Albiglutide Harmony 7 Clinical Trial: Results
  • Table 5.10 Albiglutide Harmony 7 Clinical Trial: Adverse Events
  • Table 5.11 Dulaglutide: Product Overview
  • Table 5.12 Trulicity®: Active / Planned Clinical Trials
  • Table 5.13 Trulicity®: AWARD Clinical Program Results
  • Table 5.14 Trulicity®: AWARD-1 Clinical Trial Results
  • Table 5.15 Trulicity®: AWARD-2 Clinical Trial Results
  • Table 5.16 Trulicity®: AWARD-3 Clinical Trial Results
  • Table 5.17 Trulicity®: AWARD-4 Clinical Trial Results
  • Table 5.18 Trulicity®: AWARD-5 Clinical Trial Results
  • Table 5.19 Trulicity®: AWARD-6 Clinical Trial Results
  • Table 5.20 Trulicity®: AWARD-9 Clinical Trial Results
  • Table 5.21 Trulicity® versus Lantus®: Phase III Clinical Trial Results
  • Table 5.22 Trulicity® versus Lantus®: Phase III Clinical Trial Adverse Events
  • Table 5.23 Trulicity® versus Victoza®: Phase III Clinical Trial Results
  • Table 5.24 Trulicity® versus Victoza®: Phase III Clinical Trial Adverse Events
  • Table 5.25 ITCA 650: FREEDOM Clinical Trial Development Program
  • Table 5.26 ITCA 650: Active / Planned Clinical Trials
  • Table 5.27 ITCA 650: FREEDOM-2 Clinical Trial Results
  • Table 5.28 PEX 168: Active / Planned Clinical Trials
  • Table 5.29 PEX 168: Clinical Trial Results
  • Table 5.30 Semaglutide: Active / Planned Clinical Trials
  • Table 5.31 Semaglutide: SUSTAIN Clinical Program Key Characteristics
  • Table 5.32 Semaglutide: SUSTAIN 1 Clinical Trial Results
  • Table 5.33 Semaglutide: SUSTAIN 1 Clinical Trial Adverse Events
  • Table 5.34 Semaglutide: SUSTAIN 3 Clinical Trial Results
  • Table 5.35 Semaglutide: SUSTAIN 2 Clinical Trial Results
  • Table 5.36 Semaglutide: SUSTAIN 5 Clinical Trial Results
  • Table 5.37 Semaglutide: SUSTAIN 4 Clinical Trial Results
  • Table 5.38 Semaglutide: SUSTAIN 4 Clinical Trial Adverse Events
  • Table 5.39 Uni-E4: Phase III Clinical Trial Results
  • Table 6.1 Alogliptin: Product Overview
  • Table 6.2 Alogliptin: Dosage Form, Regimen and Price
  • Table 6.3 Alogliptin: Active / Planned Clinical Trials
  • Table 6.4 Alogliptin EXAMINE Program: Dose and % Recipient Population
  • Table 6.5 Alogliptin ENDURE Trial: Drug and Dosage Combinations
  • Table 6.6 Trelagliptin: Active / Planned Clinical Trials
  • Table 6.7 Omarigliptin: Phase III Clinical Trial Adverse Events
  • Table 6.8 Evogliptin: Active / Planned Clinical Trials
  • Table 6.9 Evogliptin: Phase II Clinical Trial Results
  • Table 6.10 Retagliptin: Active / Planned Clinical Trials
  • Table 7.1 Canagliflozin: Product Overview
  • Table 7.2 Canagliflozin: Dosage Form, Regimen and Price
  • Table 7.3 Canagliflozin: Active / Planned Clinical Trials
  • Table 7.4 Canagliflozin as Monotherapy in Older Type II Diabetic Patients: Phase III Clinical Trial Results
  • Table 7.5 INVOKANA®: First Real-World Analysis
  • Table 7.6 INVOKANA®: Second Real-World Analysis
  • Table 7.7 INVOKANA®: Third Real-World Analysis
  • Table 7.8 Luseogliflozin: Active / Planned Trials
  • Table 7.9 Tofogliflozin: Active / Planned Clinical Trials
  • Table 7.10 Empagliflozin: Product Overview
  • Table 7.11 Empagliflozin: Dosage Form, Regime and Price
  • Table 7.12 Empagliflozin: Active / Planned Clinical Trials
  • Table 7.13 Empagliflozin: Retrospective Data (After 12 weeks)
  • Table 7.14 Empagliflozin: Retrospective Data (After 24 weeks)
  • Table 7.15 Glyxambi®: Phase III Clinical Trial Results
  • Table 7.16 Glyxambi®: Phase III Clinical Trial Adverse Events
  • Table 7.17 Ipragliflozin: Active / Planned Clinical Trials
  • Table 7.18 Ipragliflozin as Combination Therapy: Phase III Clinical Trial Results
  • Table 7.19 Bexagliflozin: Phase II Clinical Trial Results
  • Table 7.20 Ertugliflozin: Active/Planned Clinical Trials
  • Table 7.21 Ertugliflozin: Phase III Clinical Trial Results (VERTIS Mono)
  • Table 7.22 Ertugliflozin: Phase III Clinical Trial Adverse Events (VERTIS Mono)
  • Table 7.23 Ertugliflozin: Phase III Clinical Trial Results (VERTIS Factorial)
  • Table 7.24 Ertugliflozin: Phase III Clinical Trial Adverse Events (VERTIS Factorial)
  • Table 7.25 Sotagliflozin: Active/Planned Clinical Trials
  • Table 7.26 Sotagliflozin: Phase IIb Study Results, Reduction in HbA1c levels
  • Table 7.27 Sotagliflozin: Phase IIb Study Results, Reduction in Blood Pressure
  • Table 7.28 Sotagliflozin: Phase IIa Study Results
  • Table 8.1 DPP4 Inhibitors: Regulatory Agencies Warnings
  • Table 8.2 SGLT2 Inhibitors: Regulatory Agencies Warnings
  • Table 8.3 DPP4 inhibitors/SGLT2 inhibitors/GLP-1 Agonists: Terminated Molecules
  • Table 9.1 List of Novel Non-Insulin Therapies for Diabetes
  • Table 11.1 GLP-1 Agonists: List of Publications
  • Table 11.2 DPP4 Inhibitors: List of Publications
  • Table 11.3 SGLT2 Inhibitors: List of Publications
  • Table 12.1 GLP-1 Agonists: List of Key Opinion Leaders
  • Table 12.2 DPP4 Inhibitors: List of Key Opinion Leaders
  • Table 12.3 SGLT2 inhibitors: List of Key Opinion Leaders
  • Table 15.1 Non-Insulin Therapies: Distribution by Drug Class
  • Table 15.2 GLP-1 Agonists: Distribution by Phase of Development
  • Table 15.3 GLP-1 Agonists: Key Players
  • Table 15.4 GLP-1 Agonists: Distribution by Route of Administration
  • Table 15.5 GLP-1 Agonists: Distribution by Dosage Frequency
  • Table 15.6 GLP-1 Agonists: Distribution by Type of Molecule
  • Table 15.7 DPP4 Inhibitors: Distribution by Phase of Development
  • Table 15.8 DPP4 Inhibitors: Key Players
  • Table 15.9 DPP4 Inhibitors: Distribution by Type of Therapy
  • Table 15.10 DPP4 Inhibitors: Distribution by Dosage Frequency
  • Table 15.11 SGLT2 Inhibitors: Distribution by Phase of Development
  • Table 15.12 SGLT2 Inhibitors: Key Players
  • Table 15.13 SGLT2 Inhibitors: Distribution by Type of Therapy
  • Table 15.14 SGLT2 Inhibitors: Distribution by Dosage Frequency
  • Table 15.15 GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Key Players
  • Table 15.16 Tanzeum® / Eperzan®: Historical Sales, 2014-Q12016 (GBP Million)
  • Table 15.17 Trulicity®: Historical Sales, 2014-2015 (USD Million)
  • Table 15.18 Trulicity® Historical Sales: Distribution by Region, 2015 (USD Million)
  • Table 15.19 Alogliptin: Historical Sales, FY2011-Q1 FY2016 (JPY Billion)
  • Table 15.20 Alogliptin Historical Sales: Distribution by Region, FY2015 (JPY Billion)
  • Table 15.21 INVOKANA® / INVOKAMET®: Historical Sales, 2013-Q1 2016 (USD Million)
  • Table 15.22 INVOKANA® / INVOKAMET® Historical Sales: Distribution by Region, 2015-Q1 2016 (USD Million)
  • Table 15.23 Terminated Molecules: Distribution by Type of Drug Class
  • Table 15.24 Terminated Molecules: Distribution by Type of Drug Class and Phase of Development
  • Table 15.25 Terminated Molecules: Distribution by Type of Drug Class and Year of Termination
  • Table 15.26 Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Drug Class
  • Table 15.27 Novel Non-Insulin Therapies for Diabetes: Distribution by Phase of Development
  • Table 15.28 Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Molecule
  • Table 15.29 Non-Insulin Therapies for Diabetes Market, 2016-2026 (USD Billion)
  • Table 15.30 Non-Insulin Therapies for Diabetes Market, 2016, 2021 and 2026: Distribution by Type of Drug Class
  • Table 15.31 GLP-1 Agonists Market, 2016-2026 (USD Billion)
  • Table 15.32 Liraglutide (1.2mg and 1.8mg) Sales Forecast, 2016-2026 (USD Million)
  • Table 15.33 Exendin-4 / ITCA 650 Sales Forecast, 2017-2026 (USD Million)
  • Table 15.34 Exenatide Extended Release Sales Forecast, 2016-2026 (USD Million)
  • Table 15.35 Dulaglutide Sales Forecast, 2016-2026 (USD Million)
  • Table 15.36 Albiglutide Sales Forecast, 2016-2026 (USD Million)
  • Table 15.37 Lixisenatide Sales Forecast, 2016-2026 (USD Million)
  • Table 15.38 Semaglutide/NN9535 Sales Forecast, 2018-2026 (USD Million)
  • Table 15.39 Liraglutide / Insulin Degludec Sales Forecast, 2016-2026 (USD Million)
  • Table 15.40 Semaglutide Oral / OGC217SC / NN9924 Sales Forecast, 2020-2026 (USD Million)
  • Table 15.41 Exenatide Sales Forecast, 2016-2026 (USD Million)
  • Table 15.42 DPP4 Inhibitors Market, 2016-2026 (USD Billion)
  • Table 15.43 Sitagliptin Sales Forecast, 2016-2026 (USD Million)
  • Table 15.44 Vildagliptin Sales Forecast, 2016-2026 (USD Million)
  • Table 15.45 Saxagliptin Sales Forecast, 2016-2026 (USD Million)
  • Table 15.46 Linagliptin Sales Forecast, 2016-2026 (USD Million)
  • Table 15.47 Alogliptin Sales Forecast, 2016-2026 (USD Million)
  • Table 15.48 Gosogliptin Sales Forecast, 2017-2026 (USD Million)
  • Table 15.49 SGLT2 Inhibitors Market, 2016-2026 (USD Billion)
  • Table 15.50 Sotagliflozin Sales Forecast, 2018-2026 (USD Million)
  • Table 15.51 Empagliflozin Sales Forecast, 2016-2026 (USD Million)
  • Table 15.52 Canagliflozin Sales Forecast, 2016-2026 (USD Million)
  • Table 15.53 Dapagliflozin Sales Forecast, 2016-2026 (USD Million)
  • Table 15.54 Tofogliflozin Sales Forecast, 2016-2026 (USD Million)
  • Table 15.55 Ertugliflozin Sales Forecast, 2018-2026 (USD Million)
  • Table 15.56 Bexagliflozin Sales Forecast, 2018-2026 (USD Million)
  • Table 15.57 Publications on GLP-1 Agonists: Distribution by Focus Drug
  • Table 15.58 Publications on DPP4 Inhibitors: Distribution by Focus Drug
  • Table 15.59 Publications on SGLT2 Inhibitors: Distribution by Focus Drug
  • Table 15.60 Overall Non-Insulin Therapies Market Forecast: Distribution by Drug Class, 2016-2026 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1 3sBio
  • 2 Aalborg Hospital
  • 3 Aarhus University Hospital
  • 4 Abbott Laboratories
  • 5 ActivX Biosciences
  • 6 Addex Therapeutics
  • 7 Aegis Therapeutics
  • 8 AGDUC
  • 9 AIDS Clinical Trials Group
  • 10 Ajinomoto
  • 11 Alantos Pharmaceuticals
  • 12 Albert Einstein College of Medicine
  • 13 Alize Pharma
  • 14 Alkem Labs
  • 15 Alkermers
  • 16 Allegheny Health Network
  • 17 Allergan
  • 18 Almirall
  • 19 Alteogen
  • 20 ALZA Pharmaceuticals
  • 21 American Association of Clinical Endocrinologists
  • 22 American Diabetes Association
  • 23 American Heart Association
  • 24 Amgen
  • 25 Amunix
  • 26 Amylin Pharmaceuticals
  • 27 AntriaBio
  • 28 ArisGen
  • 29 Arisaph Pharmaceuticals
  • 30 Asan Medical Center
  • 31 Ascendis Pharma
  • 32 Assistance Publique Hopitaux De Marseille
  • 33 Astellas Pharma
  • 34 AstraZeneca
  • 35 Atlanta VA Medical Center
  • 36 Audie L. Murphy VA Hospital
  • 37 Aventis
  • 38 Avexxin
  • 39 Banyu Pharmaceutical
  • 40 Bayer Pharmaceuticals
  • 41 Baylor College of Medicine
  • 42 Baylor Research Institute
  • 43 Beijing Tongren Hospital
  • 44 Besançon Regional University Hospital
  • 45 Beth Israel Deaconess Medical Center
  • 46 BHV Pharma
  • 47 Bio-Ker
  • 48 Biolaxy
  • 49 BioLineRx
  • 50 Birmingham City Hospital
  • 51 Bispebjerg Hospital
  • 52 Boehringer Ingelheim
  • 53 Boramae Medical Center
  • 54 Boston Medical Center
  • 55 Brigham and Women's Hospital
  • 56 Bristol-Myers Squibb
  • 57 C4XD
  • 58 Cadila Healthcare Limited
  • 59 Cambridge Healthtech Institute
  • 60 Carl T. Hayden Medical Research Foundation
  • 61 Cedars-Sinai Medical Center
  • 62 Celerion
  • 63 Celgene
  • 64 CellMed
  • 65 Center for Human Drug Research
  • 66 Centers for Disease Control and Prevention
  • 67 Centre for Prognosis Studies in the Rheumatic Diseases
  • 68 Centre Hospitalier De Valenciennes
  • 69 Centre Hospitalier Sud Francilien
  • 70 Centre Hospitalier Universitaire Amiens
  • 71 Centro de Diabetes Curitiba
  • 72 CERITD
  • 73 Chang Gung Memorial Hospital
  • 74 Charles Drew University of Medicine and Science
  • 75 Charles University
  • 76 ChemRar High Tech Center
  • 77 Children's Healthcare of Atlanta
  • 78 Children's Heart Surgery Fund
  • 79 Children's Hospital of Philadelphia
  • 80 China-Japan Friendship Hospital
  • 81 Chinese PLA General Hospital
  • 82 Chinese University of Hong Kong
  • 83 Chonbuk National University Hospital
  • 84 CHU de Québec
  • 85 CHU Dijon
  • 86 Chugai Pharmaceutical
  • 87 Cincinnati Children's Hospital Medical Center
  • 88 Clinical Pharmacology Unit, Belgium
  • 89 Clinique Saint-Anne Strasbourg
  • 90 Clinique Sainte-Anne - AURAL Strasbourg
  • 91 Colorado State University
  • 92 Committee for Medicinal Products for Human Use
  • 93 ConjuChem Biotechnologies
  • 94 Connexios Life Sciences
  • 95 Copenhagen University Hospital
  • 96 Cornell CRS
  • 97 CoSynance Therapeutics
  • 98 CSL Behring
  • 99 CSPC Pharma
  • 100 CureDM
  • 101 CymaBay Therapeutics
  • 102 Daewoong Pharmaceutical
  • 103 Daiichi Sankyo
  • 104 Dainippon Sumitomo Pharma
  • 105 Dance Biopharm
  • 106 Diabetes Foundation
  • 107 Diabeteszentrum Bad Lauterberg
  • 108 Diabetes-Zentrum Quakenbruck
  • 109 Diabetology
  • 110 Diamyd Medical
  • 111 Diartis Pharmaceuticals
  • 112 Dokkyo Medical University
  • 113 Dong-A Pharmaceutical
  • 114 Dongguk University College of Medicine
  • 115 Double-Crane Pharmaceutical
  • 116 Dr. A. Ramachandran's Diabetes Hospital
  • 117 Duke University
  • 118 Eisai
  • 119 Eli Lilly
  • 120 Emisphere Technologies
  • 121 Emory University
  • 122 Eurofarma
  • 123 European Association for the Study of Diabetes
  • 124 Farallon Capital Management
  • 125 Federal University of Rio Grande do Sul
  • 126 Ferring Pharmaceutical
  • 127 Flamel Technologies
  • 128 Foresee Pharmaceuticals
  • 129 Foresite Capital
  • 130 Forest Laboratories
  • 131 Franklin Templeton
  • 132 Fred Alger Management
  • 133 Friedrich-Alexander-Universität Erlangen-Nürnberg
  • 134 Fudan University
  • 135 Fundação Faculdade Regional de Medicina de São José do Rio Preto
  • 136 Fuwai Hospital
  • 137 GalaxoSmithKline
  • 138 Gastroenterology Department Erasme Hospital
  • 139 General Hospital of People's Liberation Army Chengdu Military Region
  • 140 Genexine
  • 141 Gentofte Hospital
  • 142 Genzyme
  • 143 Geropharm
  • 144 Glasgow Royal Infirmary
  • 145 Glenmark Pharmaceuticals
  • 146 Glide Technologies
  • 147 Grady Memorial Hospital
  • 148 Greensboro CRS
  • 149 Guy's and St Thomas' Hospitals
  • 150 GWT-TUD
  • 151 Hadassah Ein Kerem
  • 152 Hadassah Medical Organization
  • 153 Handok Pharmaceuticals
  • 154 Hanmi Pharmaceuticals
  • 155 Harvard University
  • 156 Hatter Cardiovascular Institute
  • 157 Haywood Regional Medical Center
  • 158 Heart Institute (InCor)
  • 159 Hebrew University
  • 160 Herlev Hospital
  • 161 Hopital cardiologique Louis Pradel
  • 162 Hospices Civils de Colmar
  • 163 Hospital Clinic of Barcelona
  • 164 Hospital Clínico de Madrid
  • 165 Hospital General Carlos Haya
  • 166 Hospital General de Segovia
  • 167 Hospital of the Holy Cross and Saint Paul
  • 168 Hospital Universitario Insular
  • 169 Houston AIDS Research Team CRS
  • 170 Hua Medicine
  • 171 Huashan Hospital
  • 172 Hvidovre University Hospital
  • 173 Hyundai Pharmaceutical
  • 174 Ildong Pharmaceutical
  • 175 Ilsan Hospital
  • 176 ImmuPharma
  • 177 Imperial College London
  • 178 Indiana University
  • 179 Institut de Recherches Cliniques de Montreal
  • 180 Institut für Pharmakologie und Präventive Medizin
  • 181 Institut National de la Santé Et de la Recherche Médicale
  • 182 Institute for Medical Research
  • 183 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
  • 184 Intarcia Therapeutics
  • 185 Intercept Pharmaceuticals
  • 186 International Diabetes Federation
  • 187 International Society for Pharmacoeconomics and Outcomes Research
  • 188 Ionis Pharmaceuticals
  • 189 Ipsen
  • 190 IRCCS Policlinico San Matteo Foundation
  • 191 Islet Lifesciences
  • 192 Janssen
  • 193 Jean Verdier Hospital
  • 194 JHL Biotech
  • 195 Jiangsu Hansoh Pharmaceutical
  • 196 Jiangsu Hengrui Medicine
  • 197 Jiangsu Provincial People's Hospital
  • 198 Johnson and Johnson
  • 199 Joslin Diabetes Center
  • 200 Jothydev's Diabetes and Research Center
  • 201 Juntendo University School of Medicine
  • 202 Juvenile Diabetes Research Foundation
  • 203 Kalypsys
  • 204 Kanazawa University
  • 205 Kangbuk Samsung Hospital
  • 206 Kansai Electric Power Hospital
  • 207 Karolinska Institutet
  • 208 Katobuki Pharmaceutical
  • 209 Kevan Herold
  • 210 Khoo Teck Puat Hospital
  • 211 Kinderkrankenhaus auf der Butl
  • 212 KineMed
  • 213 King's College London
  • 214 Kirchhain
  • 215 Kissei Pharmaceutical
  • 216 Koege University Hospital
  • 217 Korea University
  • 218 Kotobuki Pharmaceutical
  • 219 Kowa Pharmaceutical
  • 220 Kurume University
  • 221 Kyorin Pharmaceutical
  • 222 Kyoto University
  • 223 Kyowa Hakko Kirin Company
  • 224 Kyunghee University Medical Center
  • 225 Laval University
  • 226 Leicester General Hospital
  • 227 Leiden University Medical Center
  • 228 Lexicon
  • 229 LG Life Sciences
  • 230 Ligand Pharmaceuticals
  • 231 Lund University
  • 232 Lunenfeld Tanenbaum Research Institute
  • 233 Lupin
  • 234 Luye Pharma Group
  • 235 Mackay Memorial Hospital
  • 236 MacroGenics
  • 237 Mannkind Corporation
  • 238 Marcadia Biotech
  • 239 Massachusetts General Hospital
  • 240 Mayo Clinic
  • 241 Medanta Medicity
  • 242 Medical College of Wisconsin
  • 243 Medical University Innsbruck
  • 244 Medical University of Graz
  • 245 Medical University of Silesia
  • 246 Medical University of Vienna
  • 247 Medico Moving Center Institute, Formosa
  • 248 MedImmune
  • 249 Menarini Group
  • 250 Merck
  • 251 Merrion Pharmaceuticals
  • 252 Metabasis Therapeutics
  • 253 Metabolic Center of Louisiana Resarch Foundation
  • 254 Mid America Heart Institute Saint Luke's Health System
  • 255 MidaSol Therapeutics
  • 256 Mitsubishi Tanabe Pharma
  • 257 Mitusui Memorial Hospital
  • 258 MonoSol Rx
  • 259 Mount Sinai Hospital, Canada
  • 260 Mountain Diabetes and Endocrine Center
  • 261 MultiMedica
  • 262 Nanjing Drum Tower Hospital
  • 263 National Cerebral and Cardiovascular Center
  • 264 National Health Research Institutes
  • 265 National Institues of Health
  • 266 National Institute for Health and Care Excellence
  • 267 National Institute of Diabetes and Digestive and Kidney Diseases
  • 268 National Institute on Aging
  • 269 National Taiwan University Hospital
  • 270 Nemours Children's Clinic
  • 271 New Enterprise Associates
  • 272 New Leaf Venture Partners
  • 273 New York Obesity Nutrition Research Center
  • 274 NIHR Exeter Clinical Research Facility
  • 275 Nobel Ilaç'
  • 276 NOD Pharmaceuticals
  • 277 Norwegian University of Science and Technology
  • 278 Novartis
  • 279 Novo Nordisk
  • 280 NU Hospital Organization
  • 281 Numab
  • 282 OctoPlus
  • 283 Ohio State University
  • 284 Ono Pharmaceutical
  • 285 OPKO Biologics
  • 286 Optum
  • 287 Oramed Pharmaceuticals
  • 288 Örebro University
  • 289 Oregon Health and Science University
  • 290 Osaka University Graduate
  • 291 Oslo University Hospital Ullevaal
  • 292 Otsuka Pharmaceutical
  • 293 Panacea Biotec
  • 294 PAREXEL International
  • 295 Park Nicollet International Diabetes Center
  • 296 PegBio
  • 297 Peking Union Medical College Hospital
  • 298 Pennington Biomedical Research Center
  • 299 People's Hospital, Peking Universty
  • 300 Peptron
  • 301 Pfizer
  • 302 Pharmaceutical Product Development
  • 303 PharmaIN
  • 304 Pharmsynthez
  • 305 PhaseBio Pharmaceuticals
  • 306 Phenomix
  • 307 Phoenix VA Healthcare System
  • 308 Phoundry Pharmaceuticals
  • 309 Pitié-Salpêtrière Hospital
  • 310 Palatin Technologies
  • 311 Pontificia Universidad Catolica de Chile
  • 312 Population Health Research Institute
  • 313 Post Graduate Institute of Medical Education and Research
  • 314 Poxel
  • 315 Prism Research
  • 316 Probiodrug
  • 317 Profil Institut für Stoffwechselforschung
  • 318 Profil Institute for Metabolic Research
  • 319 Prosidion
  • 320 Pusan National University Hospital
  • 321 Pusat Perubatan Universiti Kebangsaan
  • 322 Qianfoshan Hospital
  • 323 Quilvest
  • 324 Quintiles
  • 325 Quotient Bioresearch Clinical Services
  • 326 RA Capital
  • 327 Radboud University
  • 328 Rani Therapeutics
  • 329 Receptos
  • 330 Rigshospitalet
  • 331 Rikshospitalet Medical Center
  • 332 Roche
  • 333 Royal Adelaide Hospital
  • 334 Royal Bournemouth Hospital
  • 335 Royal Devon & Exeter NHS Trust
  • 336 Royal Surrey County Hospital
  • 337 Royalty Pharma
  • 338 Ruhr-University Bochum
  • 339 Saint Luke's Mid America Heart Institute
  • 340 Samsung Medical Center
  • 341 Sana Klinikum Offenbach
  • 342 Sanofi
  • 343 Sanwa Kagaku Kenkyusho
  • 344 Sao Paulo General Hospital
  • 345 SatRx
  • 346 Scientisic Research Institute of Cardiology and Internal Diseases
  • 347 ScinoPharm
  • 348 Seattle Children's Hospital
  • 349 Second University of Naples
  • 350 Second Xiangya Hospital of Central South University
  • 351 Seoul National University Bundang Hospital
  • 352 Seoul St. Mary's Hospital
  • 353 Serometrix
  • 354 Services Hospital
  • 355 Servier
  • 356 Severance Hospital
  • 357 Shandong Provincial Hospital
  • 358 Shanghai Jiao Tong University School of Medicine
  • 359 Shanghai Mental Health Center
  • 360 Shanghai Sixth People's Hospital
  • 361 Sheba Medical Center
  • 362 Sirona Biochem
  • 363 Slotervaart Hospital
  • 364 Spitfire Pharma
  • 365 St Michael's Hospital
  • 366 St. Josef Hospital
  • 367 St. Joseph's Health Care, London
  • 368 Stanford University
  • 369 Stendhal
  • 370 Steno Diabetes Center
  • 371 Sumitomo Dainippon Pharma
  • 372 Sun Pharma Advanced Research
  • 373 Sun Yat-Sen University
  • 374 Sydney Diabetes Centre
  • 375 Taichung Veterans General Hospital
  • 376 Taipei Medical University WanFang Hospital
  • 377 Taisho Pharmaceutical
  • 378 Takeda
  • 379 Tampere University Hospital
  • 380 Tarix Pharmaceuticals
  • 381 Teijin Pharma
  • 382 Teva Active Pharmaceutical Ingredients
  • 383 The Baupost Group
  • 384 The Catholic University of Korea
  • 385 The First Affiliated Hospital of Xi'an Jiaotong University
  • 386 The First Affiliated Hospital of Xiamen University
  • 387 The First Affiliated Hospital of Zhejiang University
  • 388 The George Institute for Global Health
  • 389 The George Washington University Medical Faculty Associates
  • 390 The National Center for Scientific Research
  • 391 The Third Xiangya Hospital of Center South University
  • 392 Theracos
  • 393 Therapix Biosciences
  • 394 Theratechnologies
  • 395 Third Military Medical University, China
  • 396 Thomas Jefferson University
  • 397 TIMI Study Group
  • 398 Tobira Therapeutics
  • 399 Tolerx
  • 400 Toronto Western Hospital
  • 401 Transition Therapeutics
  • 402 TransTech Pharma
  • 403 Tulane University
  • 404 Turku PET Centre
  • 405 Turku University Hospital
  • 406 UCL Institute of Neurology
  • 407 UKMMC
  • 408 UMass Medical School
  • 409 Uni-Bio Science Group
  • 410 Universität zu Lübeck
  • 411 Université de Lorraine
  • 412 Université de Montréal
  • 413 University at Buffalo
  • 414 University College Dublin
  • 415 University Health Network
  • 416 University Hospital Center of Toulouse
  • 417 University Hospital of Basel
  • 418 University Hospital of Caen
  • 419 University Hospital of Palermo
  • 420 University Medical Center Groningen
  • 421 University Medical Center Hamburg-Eppendorf
  • 422 University Medical Center Ljubljana,Slovenia
  • 423 University Nijmegen Medical Center
  • 424 University of Aarhus
  • 425 University of Adelaide
  • 426 University of Alabama at Birmingham
  • 427 University of Alberta
  • 428 University of Amsterdam
  • 429 University of Birmingham
  • 430 University of Bordeaux
  • 431 University of British Columbia
  • 432 University of California
  • 433 University of California, Davis
  • 434 University of California, Los Angeles
  • 435 University of Chicago
  • 436 University of Cincinnati
  • 437 University of Colorado
  • 438 University of Copenhagen
  • 439 University of Dundee
  • 440 University of Exeter
  • 441 University of Geneva
  • 442 University of Guadalajara
  • 443 University of Illinois at Chicago
  • 444 University of Leicester
  • 445 University of Manchester
  • 446 University of Maryland
  • 447 University of Miami
  • 448 University of Michigan
  • 449 University of Minnesota
  • 450 University of Munich
  • 451 University of Nebraska-Lincoln
  • 452 University of Nevada School of Medicine
  • 453 University of North Carolina, Chapel Hill
  • 454 University of Nottingham
  • 455 University of Oulu
  • 456 University of Padova Medical School
  • 457 University of Palermo
  • 458 University of Pennsylvania
  • 459 University of Pittsburgh
  • 460 University of São Paulo General Hospital
  • 461 University of Southern California
  • 462 University of Surrey
  • 463 University of Tartu
  • 464 University of Texas
  • 465 University of Texas Health Science Center
  • 466 University of Texas Medical Branch
  • 467 University of the Ryukyus
  • 468 University of Tokyo
  • 469 University of Toronto
  • 470 University of Washington
  • 471 University of Western Ontario
  • 472 Uppsala University
  • 473 UT Southwestern Medical Center
  • 474 VA Puget Sound Health Care System
  • 475 Vall d'Hebron Research Institute
  • 476 Vanderbilt University School of Medicine
  • 477 Velocity Pharmaceutical Development
  • 478 Venrock
  • 479 Viking Therapeutics
  • 480 Vitae Pharmaceuticals
  • 481 VIVUS
  • 482 vTv Therapeutics
  • 483 VU University Medical Center
  • 484 Wake Forest University / Wake Forest University Health Sciences
  • 485 Walter Reed Army Medical Center- Diabetes Institute
  • 486 Wan Fang Hospital
  • 487 Wanbang Biopharmaceuticals (subsidiary of Shanghai Pharmaceutical Group)
  • 488 Washington University CRS
  • 489 Washington University School of Medicine
  • 490 Woman's Hospital
  • 491 World Health Organization
  • 492 Wuhan General Hospital of Guangzhou Command
  • 493 Xenetic Biosciences
  • 494 Yale University
  • 495 Yeshiva University
  • 496 Yokohama City University School of Medicine
  • 497 Yuhan
  • 498 Zealand Pharma
  • 499 Zosano Pharma
  • 500 Zydus Cadila
  • 501 ZymoGenetics
Back to Top